Incyte’s Dual Strategy to Navigate Patent Cliff
Published on 09/25/2025 at 06:09 | Redaktion boerse-global.de
As the patent protection for its blockbuster drug Jakafi approaches expiration, biopharmaceutical firm Incyte is implementing a two-pronged strategy to secure its long-term future. The company is bolstering its product pipeline through a significant regulatory approval and a key executive appointment.
This week, Incyte announced that Dave Gardner has joined the company as Executive Vice President and Chief Strategy Officer. Mr. Gardner brings more than two decades of experience in pharmaceutical investments to the role, where he will be responsible for optimizing Incyte’s development pipeline and identifying new growth opportunities. His compensation package is heavily tied to the company’s long-term performance, highlighting the importance of his strategic position. This appointment follows the departure of former CFO Christiana Stamoulis in mid-September.
Simultaneously,... Read more...
Disclaimer regarding our articles: No investment advice, no buy or sell recommendation. Information on prices, companies, and markets is provided without guarantee; changes are possible at any time. Stock market transactions can lead to substantial losses. Our articles are created and reviewed in whole or in part automatically with the support of AI.
